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In cross-sectional studies increased vaginal bacterial diversity has been associated with vaginal 
inflammation which can be detrimental for health. We describe longitudinal changes at 5 visits over 8 
weeks in vaginal microbiota and immune mediators in African women. Women (N = 40) with a normal 
Nugent score at all visits had a stable lactobacilli dominated microbiota with prevailing Lactobacillus 
iners. Presence of prostate-specific antigen (proxy for recent sex) and being amenorrhoeic (due 
to progestin-injectable use), but not recent vaginal cleansing, were significantly associated with 
microbiota diversity and inflammation (controlled for menstrual cycle and other confounders). Women 
(N = 40) with incident bacterial vaginosis (Nugent 7–10) had significantly lower concentrations of 
lactobacilli and higher concentrations of Gardnerella vaginalis, Atopobium vaginae, and Prevotella 
bivia, at the incident visit and when concentrations of proinflammatory cytokines (IL-1β, IL-12p70) 
were increased and IP-10 and elafin were decreased. A higher ‘composite-qPCR vaginal-health-score’ 
was directly associated with decreased concentrations of proinflammatory cytokines (IL-1α, IL-8, 
IL-12(p70)) and increased IP-10. This longitudinal study confirms the inflammatory nature of vaginal 
dysbiosis and its association with recent vaginal sex and progestin-injectable use. A potential role 
for proinflammatory mediators and IP-10 in combination with the vaginal-health-score as predictive 
biomarkers for vaginal dysbiosis merits further investigation.
The vaginal mucosal surface is colonised by a variety of bacterial species and the composition, which has impli-
cations for reproductive health, is influenced by both endogenous and exogenous factors (reviewed in1). Using 
culture-dependent and molecular amplification techniques (such as quantitative polymerase chain reaction 
(qPCR) and next generation sequencing), a ‘normal’ vaginal microbiota (VMB) has been defined as one domi-
nated by lactic acid-producing Lactobacillus species. The clinical condition bacterial vaginosis (BV) is associated 
with increased diversity and quantity of bacteria and a concomitant decrease in lactobacilli2. Molecular studies 
have shown some lactobacilli (notably L. crispatus) are more associated with health than others (L. iners) because 
they are associated with a lower risk of developing vaginal dysbiosis3 or acquiring sexually transmitted infections 
(STIs)4.
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BV is the most common vaginal dysbiosis1 and has been associated with adverse clinical outcomes includ-
ing pre-term birth and miscarriage5, pelvic inflammatory disease6, and the acquisition and transmission of STIs 
including HIV7–10. It has been suggested that such adverse outcomes are directly associated with inflammatory 
or immune activation cascades triggered by vaginal dysbiosis11. For example, inflammation triggered by vaginal 
dysbiosis probably attracts CD4 + cells to the cervicovaginal mucosa, thereby increasing the availability of target 
cells for HIV at the site of viral entry into the body12.
Sub-Saharan Africa has the highest prevalence of BV13 but diagnosis is often missed because symptoms are 
frequently absent or nonspecific, and the microscopic methods necessary for diagnosis by Amsel criteria or 
Nugent14 scoring are typically not available. Cross-sectional studies using molecular techniques have confirmed 
the high prevalence of vaginal dysbiosis in sub-Saharan Africa and have also shown that L. iners dominated VMB 
are more frequent than those dominated by L. crispatus15,16. Sub-Saharan African women may therefore be less 
protected from vaginal dysbiosis, even when they have a lactobacilli-dominated VMB.
Information on fluctuations in the VMB over time is limited, but studies17,18 have shown the variation within 
an individual over time is more pronounced than the variation between individuals19, and that such changes are 
influenced by the menstrual cycle and can occur rapidly17,20.
We conducted a longitudinal cohort study (the Vaginal Biomarkers Study) in 430 women at three sites in 
Kenya, Rwanda and South Africa21. The study visits were tightly scheduled to control for the menstrual cycle. We 
selected 40 women with consistently normal VMB (defined as a Nugent score of 0–3) at five study visits over eight 
weeks and 40 women who developed BV (Nugent score of 7–10) during the same eight-week period. The primary 
objective of this sub-study was to describe the vaginal bacterial species and concentrations of vaginal immune 
mediators in these cohorts over time. Secondary objectives included the determination of host correlates of vag-
inal bacteria and immune mediators, any associations between them and those which occurred around the time 
of incident BV diagnosis. This is the first longitudinal study to describe the composition of the VMB and vaginal 
immune mediators in quantitative terms over time as well as any associations between them whilst controlling 
for menstrual cycle and other factors known to be associated with changes in the vaginal micro-environment.
Results
The cross-sectional characteristics of all 430 women enrolled in the Vaginal Biomarkers Study, including the com-
position of the VMB, have been previously described15,16,21,22. In this sub-study, the median age of the 40 women 
with a consistently normal VMB (reference group) and the 40 women who developed incident BV (incident BV 
group) was 23 and 24 years respectively (ranges 16–34 years and 16–33 years). The median age at first vaginal 
intercourse was 17 years for both groups. Half of the women with a consistently normal VMB (53%) and 43% of 
the women who developed BV had had two or three lifetime sex partners with most (78% and 88%, respectively) 
having had one sex partner in the last three months. Over fifty percent of the women in both groups had deliv-
ered a child at least once. Most women in both groups (80%) currently used contraception: 36% used progestin 
injections, 13% used combined hormonal pills, 5% were sterilised, and 26% used condoms only. All women in the 
reference group tested negative for pregnancy, HIV, syphilis, Neisseria gonorrhoeae, Chlamydia trachomatis, and 
Trichomonas vaginalis, by design. The baseline herpes simplex virus type 2 (HSV-2) prevalence was 30% in the 
women with a consistently normal VMB and 33% in the women who developed BV.
Table 1 describes participant characteristics by group over the five study visits for those parameters that were 
subsequently included in mixed effects regression models as potential confounders of the main associations of 
interest between VMB bacteria and vaginal immune mediators (see methods). The reference group included 
HIV-negative adult women (N = 16 Kenya, N = 16 South Africa), adolescents (N = 6 Kenya), and HIV-negative 
sex workers (N = 2 Rwanda). The incident BV group included HIV-negative adult women (N = 16 Kenya, N = 11 
South Africa), adolescents (N = 5 Kenya, N = 2 South Africa), pregnant women (N = 1 Kenya, N = 3 South 
Africa); and HIV-negative sex workers (N = 2 Rwanda). The detection of prostate-specific antigen (PSA) in the 
vagina as a marker of vaginal sex in the last 24–48 hours23,24 and self-reported vaginal cleansing in the evening or 
morning just prior to the study visit were both common (25–57% and 28–53% at different visits, respectively). 
Clinician-observed abnormal vaginal discharge and cervical mucus were also common, but cervical epithelial 
findings visible by the naked eye (abrasion, laceration, ecchymosis, petechiae, erythema, or ulcer) were uncom-
mon (occurring in 1–8 women at each visit), throughout the study (Table 1). At all visits, a substantial proportion 
of women (up to 33% of the women with a consistently normal VMB and up to 68% of the women who developed 
BV) had a vaginal pH above 4.5, which is considered outside the normal range and is one of the Amsel criteria 
for the diagnosis of BV25.
VMB bacteria and Candida over time (reference group). The presence of individual VMB bacteria 
and Candida albicans was determined by qPCR and expressed as log10 genome equivalents (geq) per millilitre 
(ml). Over the five visits, presence was classified as: never present (0% of visits); sporadically present (1–25% of 
visits); regularly present (26–74% of visits) and consistently present (75–100% of visits). The presence of individ-
ual Lactobacillus species was relatively stable over the five visits in the reference group; i.e. either consistently or 
never present (Figs 1 and 2). This was particularly true of L. crispatus, which was consistently present in 47% of 
women or never present in 53% of women (Fig. 2). In 79% of the women with consistent L. crispatus, this was 
accompanied by a consistent or regular presence of L. vaginalis (Fig. 1). L. iners was consistently present in 75% of 
women and regularly present in another 10% of women. L. iners and L. crispatus did occur together at least twice 
in 35% of women, but women with high concentrations of L. crispatus had lower concentrations of L. iners and 
vice versa (Fig. 1). C. albicans, L. jensenii and L. gasseri were never present in 60%, 63% and 75% of the women, 
respectively. Escherichia coli was present (but always in a lower concentration than the lactobacilli) at least once in 
90% of women, Prevotella bivia in 91% of women, Gardnerella vaginalis in 58% of women, and Atopobium vaginae 
in only 17% of women.
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Correlates of longitudinal variations in the concentrations of VMB bacteria were assessed in mixed effects 
linear regression models for those VMB bacteria that were consistently present in at least 25% of the women in 
the reference group. Each model had one such VMB bacteria concentration as the outcome, individual women 
as random effects, and presence or absence of a menstrual cycle, menstrual cycle phase (follicular or luteal phase; 
see methods), presence of vaginal PSA, and recent vaginal cleansing as fixed effects. It is important to note that 
all amenorrhoeic women in this sub-study were progestin injection users. The models showed that changes in 
the concentrations of VMB bacteria over time were larger within women than they were between women, with 
the exception of L. jensenii (Table 2). The mean Lactobacillus genus concentration in amenorrhoeic women was 
lower (−0.55 log10 geq/ml; p = 0.023) than the mean concentration in women with a menstrual cycle (Table 2), 
with L. crispatus accounting for the greatest difference (Table 2). The mean Lactobacillus genus (−0.39 log10 geq/
ml; p = 0.010), L. iners (−0.75 log10 geq/ml; p = 0.008) and P. bivia (−0.38 log10 geq/ml; p = 0.045) concentrations 
were significantly lower at visits with vaginal PSA detected (Table 2). The mean E. coli concentration was signifi-
cantly lower at luteal phase visits compared to follicular phase visits in women with a menstrual cycle (−0.75 log10 
geq/ml; p = 0.020). There were no significant associations between recent vaginal cleansing and concentration of 
any VMB bacteria (Table 2).
Vaginal immune mediators over time (reference group). Concentrations of various cytokines, 
chemokines, and growth factors were measured in cervicovaginal lavages (CVLs) and expressed in log10 pg/ml 
(see methods). Mixed effects linear regression models with each immune mediator concentration as the out-
come, individual women as random effects, and menstrual cycle presence and phase as fixed effects showed that 
changes in concentrations of immune mediators over time were larger within women than they were between 
women, with the exception of interleukin (IL)−1α (Table 3). The mean IL-1α concentration was significantly 
higher in luteal phase relative to follicular phase visits (0.16 log10 pg/ml; p = 0.004) but mean IL-6 (−0.26 log10 pg/
ml; p < 0.001), CC chemokine macrophage inflammatory protein (MIP)−1β (−0.26 log10 pg/ml; p < 0.001) and 
Characteristics of women with a normal VMB throughout
Visit 1 
(n = 40)
Visit 2 
(n = 40)
Visit 3 
(n = 40)
Visit 4 
(n = 40) Visit 5 (n = 40)
Vaginal PSA present 11 (27.5) 11 (27.5) 10* (25.0) 11 (27.5) 16 (40.0)
Vaginal cleansing during bathing this morning or last night 16 (40.0) 12 (30.0) 11 (27.5) 11 (27.5) 11 (27.5)
Clinician-observed abnormal vaginal discharge 7 (17.5) 10 (25.0) 10 (25.0) 10 (25.0) 16 (40.0)
Clinician-observed cervical mucus present 13 (32.5) 11* (28.2) 15 (37.5) 17 (42.5) 16 (40)
Clinician-observed cervical epithelial abnormalities present† 6 (15.0) 4 (10.0) 4 (10.0) 4 (10.0) 8 (20.0)
Petechiae 5 (12.5) 3 (7.5) 2 (5.0) 3 (7.5) 3 (7.5)
Erythema 1 (2.5) 0 1 (2.5) 1 (2.5) 4 (10.0)
Ecchymosis 0 1 (2.5) 1 (2.5) 0 0
Ulcer 0 0 0 0 1 (2.5)
Vaginal pH < 4 8 (20.0) 9 (22.5) 13 (33.3) 11 (27.5) 9 (22.5)
4–4.5 19 (47.5) 20 (50.0) 17 (43.6) 16 (40.0) 22 (55.0)
4.6–5 10 (25.0) 9 (22.5) 6 (15.4) 11 (27.5) 7 (17.5)
>5 3 (7.5) 2 (5.0) 3 (7.5) 2 (5.0) 2 (5.0)
Characteristics of women with incident BV Visit 1 (n = 40)
Visit 2 
(n = 40)
Visit 3 
(n = 40)
Visit 4 
(n = 40) Visit 5 (n = 40)
Vaginal PSA present 12 (30.8) 18 (48.7) 21 (56.8) 15 (40.5) 14 (43.8)
Vaginal cleansing during bathing this morning or last night 21 (52.5) 15 (38.5) 14 (35.0) 16 (41.0) 13 (33.3)
Clinician-observed abnormal vaginal discharge 5 (20.5) 6 (15.4)* 13 (32.5) 11 (28.2)* 11 (29.0)**
Clinician-observed cervical mucus present 14 (35.0) 10 (25.6)* 10 (25.0) 12 (30.8)* 14 (36.8)**
Clinician-observed cervical epithelial abnormalities presentǁ 5 (12.5) 3 (7.7)* 2 (5.0) 3 (7.7)* 3 (7.7)*
Petechiae 3 (7.5) 0 1 (2.5) 0 1 (2.6)
Ecchymosis 1 (2.5) 1 (2.6) 0 0 0
Erythema 0 1 (2.6) 0 1 (2.6) 2 (5.1)
Laceration 1 (2.5) 1 (2.6) 0 1 (2.6) 0
Ulcer 0 0 1 (2.5) 0 0
Abrasion 0 0 0 1 (2.6) 0
Vaginal pH < 4 4 (10.0) 4 (10.5) 3 (7.5) 1 (1.6) 3 (7.9)
4–4.5 22 (55.0) 16 (42.1) 10 (25.0) 16 (41.0) 10 (26.3)
4.6–5 12 (30.0) 8 (21.1) 13 (32.5) 16 (41.0) 16 (42.1)
>5 2 (5.0) 10 (26.3) 14 (35.0) 6 (15.4) 9 (23.7)
Table 1. The prevalence of participant characteristics at each study visit. Abbreviations: PSA = prostate specific 
antigen; VMB = vaginal microbiota. Data are number of women with the characteristic (% of total number of 
women). Cervical mucus presence includes mild, moderate or abundant mucus. * One missing value. ** Two 
missing values. † 26 events in 13 participants. ǁ16 events in ten participants.
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granulocyte colony-stimulating factor (G-CSF) concentrations (−0.26 log10 pg/ml; p = 0.007) were significantly 
lower. Mean concentrations of IL-8 (0.28 log10 pg/ml; p = 0.016), IL-12(p70) (0.15 log10 pg/ml; p = 0.038) and 
MIP-1β (0.34 log10 pg/ml; p = 0.013) were higher in amenorrhoeic women compared to women with a menstrual 
cycle. Further mixed effects linear regression models with each immune mediator as the outcome, individual 
women as random effects, and presence and phase of the menstrual cycle as fixed effects, were fitted with the 
following additional fixed effects added (in separate models): vaginal pH category (<4.0, 4.0–4.5, >4.5); presence 
of abnormal vaginal discharge, cervical mucus, a cervical epithelial finding, or vaginal PSA; and recent vaginal 
cleansing. Visits with PSA detected had significantly higher mean concentrations of IL-6, IL-12(p70), and CXC 
chemokines interferon (IFN)-γ-inducible protein (IP-10); visits with a higher vaginal pH had a higher mean 
concentration of IL-1RA and a lower mean concentration of secretory leucocyte peptidase inhibitor (SLPI); visits 
with abnormal vaginal discharge had lower mean concentrations of IL-1α, IL-1RA, GM-CSF and elafin; visits 
with cervical mucus had a lower mean concentration of elafin; and visits with cervical epithelial findings had a 
lower mean concentration of granulocyte macrophage colony stimulating factor (GM-CSF) (Table 3). Recent 
vaginal cleansing was not significantly associated with concentrations of any of the immune mediators (data not 
shown).
VMB bacteria, Candida, and immune mediators over time (incident BV group). All women in 
this cohort had a Nugent score of 0–3 at visit 1 (enrolment). The first visit during which BV was diagnosed was 
Figure 1. Presence/absence and concentration of vaginal microbiota bacteria over the eight week study period 
in women with a Nugent score of 0–3 throughout. Each box depicts one visit for a particular woman. The 
shading of the box indicates the concentration (in log10 geq/ml) of each taxon with darker colours depicting a 
higher concentration. If the taxon was absent, the box is white.
Figure 2. Frequency of vaginal microbiota presence over the eight week study period in women with a Nugent 
score of 0–3 throughout. Data in Y-axis are % of women. Sporadically present: present at 25% or fewer visits; 
regularly present: present at 26–74% of visits; consistently present: present at 75% or more visits.
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visit 2 in 16 women, visit 3 in seven women, visit 4 in 11 women, and visit 5 in six women (Fig. 3). Two women 
had an intermediate VMB (Nugent score 4–6) prior to an incident BV visit. At the first visits during which BV 
was detected, the mean concentrations of Lactobacillus genus (−1.51 log10 geq/ml; p = 0.005) and L. vaginalis 
(−1.35 log10 geq/ml; p = 0.021) were statistically significantly lower, and the mean concentrations of G. vaginalis 
(2.84 log10 geq/ml; p < 0.001), A. vaginae (3.92 log10 geq/ml; p < 0.001), and P. bivia (1.38 log10 geq/ml; p = 0.003) 
higher, than the mean concentrations at the preceding visit. (Table 4). C. albicans, L. jensenii and L. gasseri were 
never present at any visits in 58%, 60% and 73% of the women, respectively. Mean concentrations of IL-1β (0.66 
log10 pg/ml; p = 0.003) and IL-12(p70) (0.22 log10 pg/ml; p = 0.024) were significantly increased, and mean con-
centrations of IP-10 (−0.39 log10 pg/ml; p = 0.046), elafin (−0.26 log10 pg/ml; p = 0.010), and total protein (−0.17 
log10 pg/ml; p = 0.026) significantly decreased, at the first BV incident visit (Table 4).
VMB bacteria and immune mediator associations over time (both groups). In mixed effects linear 
regression models including all 80 women and controlled for presence and phase of menstrual cycle and PSA 
presence, a higher ‘composite qPCR vaginal health score’ was associated with a higher IP-10 concentration (2.53 
log10 pg/ml; p < 0.001) and lower IL-1α (−1.14 log10 pg/ml; p = 0.005), IL-8 (−1.55 log10 pg/ml; p = 0.002), and 
IL-12(p70) (−1.80 log10 pg/ml; p < 0.001) concentrations (Table 5). This vaginal health score was calculated as 
[log10 geq/ml (Lactobacillus genus)−log10 geq/ml (G. vaginalis + A. vaginae)] and a higher score therefore sug-
gests better vaginal health26. The Lactobacillus genus concentration (which is one component of the vaginal health 
score) showed a similar pattern except that it was not significantly associated with the IL-1α concentration and 
the reduction in IL-12(p70) concentration did not reach statistical significance. The L. crispatus and L. vaginalis 
concentrations were not significantly associated with any immune mediator concentrations over time. The L. 
iners concentration was significantly positively associated with IP-10 and IL-8 concentrations and negatively 
associated with IL-1α concentration. The P. bivia concentration was positively associated with the IL-1α and 
IL-8 concentrations and negatively associated with the IP-10 concentration, and the E. coli concentration was 
positively associated with the IL-8 concentration.
Discussion
In this longitudinal study of young sub-Saharan African women, we confirmed that a Nugent score of 0–3 over an 
eight week period was associated with consistently high concentrations of Lactobacillus species (regularly accom-
panied by much lower concentrations of the BV-associated bacteria G. vaginalis, A. vaginae, and P. bivia and the 
pathobiont E. coli), whereas incident BV was associated with significantly reduced concentrations of lactobacilli 
and increased concentrations of G. vaginalis, A. vaginae and P. bivia, but not E. coli. In women with a normal 
VMB throughout the study, VMB variations were larger within women over time than between women, as has 
been seen in other studies19. L. iners and L. crispatus were the dominant lactobacilli in our study, as has been seen 
in studies enrolling Caucasian European and American women2,27,28. However, the following of our findings have 
VMB bacteria
Women with cycle, follicular 
phase visits
Women with cycle, 
luteal phase visits vs 
follicular phase visits
Amenorrhoea (all visits) 
vs women with cycle  
(all visits)
Visits with PSA present vs 
not, among follicular phase 
visits with no recent vaginal 
cleansing reported
Visits with recent vaginal 
cleansing reported vs not, 
among follicular phase 
visits with PSA absent
Mean 
conc1
SD 
between2
SD 
within2 Mean diff3 p4 Mean diff5 p4 Mean diff6 p4 Mean diff7 p4
Lactobacillus genus 7.62 0.60 0.73 0.20 0.124 −0.55 0.023 −0.39 0.010 −0.27 0.146
L. crispatus 6.76 1.34 1.56 0.49 0.245 −1.33 0.091 −0.30 0.529 −0.05 0.939
L. iners 8.36 0.62 1.29 −0.25 0.356 0.08 0.811 −0.75 0.008 −0.32 0.272
L. jensenii 5.79 1.41 1.32 0.85 0.066 −0.30 0.785 0.36 0.476 0.12 0.842
L. vaginalis 5.84 0.92 1.31 −0.19 0.545 0.75 0.192 0.01 0.980 0.50 0.239
E. coli 5.26 <0.001 1.18 −0.75 0.020 0.14 0.637 0.10 0.757 −0.26 0.373
P. bivia 3.00 0.31 0.81 −0.16 0.346 0.27 0.199 −0.38 0.045 0.03 0.880
Table 2. Mean differences in VMB bacteria concentrations in women with a Nugent score of 0–3 during 
five visits over eight weeks by presence and phase of the menstrual cycle, presence of PSA and recent 
vaginal cleansing. Abbreviations: conc = concentration; diff = difference; PSA = prostate-specific antigen; 
SD = standard deviation; VMB = vaginal microbiota; vs = versus. 1Expressed in log10 genome equivalents per 
mL (geq/ml). The expected value for women with a menstrual cycle in the follicular phase of the cycle. 2The 
between-women and within-women standard deviations. 3The mean difference in concentration (log10 geq/
ml) between the luteal and follicular phases of the cycle for women with a menstrual cycle. 4From the mixed 
effects linear regression models with each item in the first column as the outcome, individual women as 
random effects, and fixed effects as described in the first row of the table. For women with the bacteria present 
during at least 75% of visits and excluding the visits during which the bacteria was absent. We only included 
VMB bacteria that were consistently present (in at least 75% of the visits) in at least 25% of women. 5The mean 
difference in concentration (log10 geq/ml) between women with amenorrhoea (all visits) and women with a 
cycle (all visits). 6The mean difference in concentration (log10 geq/ml) between visits with PSA present versus 
not present for visits with the same presence and phase of menstrual cycle and the same vaginal cleansing status. 
7The mean difference in concentration (log10 geq/ml) between visits at which reporting recent vaginal cleansing 
was reported versus not reported among visits with the same presence and phase of menstrual cycle and the 
same PSA status.
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A. Immune 
mediators
Women with cycle, follicular phase visits
Women with cycle, luteal 
phase vs follicular phase 
visits
Amenorrhoea (all visits) 
vs women with cycle (all 
visits)
Mean conc1 SD between2 SD within2 Mean diff5 p3 Mean diff6 p3
Total protein 8.17 0.21 0.24 0.03 0.447 0.15 0.071
IL-1α 1.10 0.36 0.30 0.16 0.004 0.15 0.253
IL-1β 0.66 0.39 0.51 −0.06 0.521 0.27 0.081
IL-6 0.78 0.42 0.50 −0.32 <0.001 0.31 0.055
IL-8 2.01 0.30 0.34 −0.06 0.334 0.28 0.016
IL-12(p70) −0.05 0.16 0.30 −0.00 0.949 0.15 0.038
IL-1RA 4.73 0.48 0.57 0.12 0.257 0.07 0.708
IP-10 2.52 0.29 0.42 −0.09 0.258 0.17 0.155
MIP-1β 0.81 0.36 0.37 −0.26 <0.001 0.34 0.013
GM-CSF 0.32 0.12 0.35 0.02 0.741 0.06 0.340
G-CSF 1.81 0.48 0.53 −0.26 0.007 0.33 0.071
Elafin 5.07 0.34 0.37 0.01 0.824 −0.12 0.333
SLPI 4.75 0.33 0.41 0.04 0.611 0.05 0.666
B. Immune 
mediators
Visits with vaginal pH 4.0–4.5 or >4.5 
vs <4
Visits with vaginal 
discharge vs not
Visits with cervical mucus 
vs not
Visits with cervical epith 
findings vs not
Visits with PSA present 
vs not
4.0–4.5 
Mean diff8
>4.5 Mean 
diff8 p
4 Mean diff9 P4 Mean diff10 p4 Mean diff11 p4 Mean diff7 p4
Total protein −0.00 −0.16 0.014 −0.07 0.150 −0.04 0.386 0.08 0.235 0.02 0.650
IL-1α 0.09 0.01 0.187 −0.13 0.024 −0.09 0.080 −0.09 0.266 0.10 0.095
IL-1β 0.14 0.07 0.366 0.07 0.464 −0.04 0.601 −0.07 0.638 0.09 0.390
IL-6 0.08 0.22 0.170 0.16 0.098 0.04 0.671 0.00 0.988 0.21 0.032
IL-8 0.09 0.06 0.409 0.06 0.355 −0.02 0.684 −0.08 0.395 0.09 0.188
IL-12(p70) 0.11 0.14 0.097 0.06 0.280 0.01 0.876 0.11 0.154 0.19 0.001
IL-1RA 0.05 0.35 0.015 −0.25 0.025 −0.14 0.132 0.05 0.734 −0.02 0.840
IP-10 0.06 −0.13 0.064 −0.04 0.611 −0.08 0.981 0.00 0.981 0.20 0.014
MIP-1β 0.14 0.14 0.163 −0.00 0.989 0.03 0.601 −0.08 0.434 0.13 0.085
GM-CSF 0.01 −0.09 0.304 −0.19 0.001 −0.01 0.926 −0.18 0.040 −0.07 0.251
G-CSF 0.06 0.03 0.844 −0.01 0.942 0.11 0.215 −0.07 0.626 0.17 0.117
Elafin 0.04 −0.02 0.678 −0.23 0.001 −0.13 0.033 0.10 0.349 0.02 0.773
SLPI 0.01 −0.20 0.034 0.01 0.899 0.07 0.288 0.08 0.489 0.14 0.103
Table 3. Mean differences in immune mediator concentrations in women with a Nugent score of 0–3 during five 
visits over eight weeks by presence and phase of the menstrual cycle (A), clinical characteristics and presence of PSA 
(B). Abbreviations: clin char = clinical characteristics; conc = concentration; diff = difference; epith = epithelial; 
G-CSF = granulocyte colony stimulating factor; GM-CSF = granulocyte macrophage colony stimulating 
factor; IL = interleukin; IP-10 = interferon-inducible protein 10; MIP-1β = macrophage inflammatory protein 
1β; PSA = prostate-specific antigen; SD = standard deviation; SLPI = secretory leukocyte protease inhibitor; 
VMB = vaginal microbiota; vs = versus. 1Expressed in log10 pg/ml. The expected value for women with a menstrual 
cycle in the follicular phase of the cycle. 2The between-women and within-women standard deviations for women 
in the model with presence and phase of the cycle as fixed effects. 3From mixed effects linear regression models 
with each item in the first column as the outcome, individual women as random effects, and including presence and 
phase of the menstrual cycle as fixed effects. 4From mixed effects linear regression models (separate model for each 
clinical characteristic and PSA) with each item in the first column as the outcome, individual women as random 
effects, and including the item in the first row as fixed effects, and controlled for presence and phase of the menstrual 
cycle. A model with recent vaginal cleansing (the evening or morning before the visit) as fixed effect controlled for 
presence and phase of the menstrual cycle was also fitted but the data are not shown because none of the findings 
were statistically significant. The clinical characteristics are clinician-observed during speculum examination. 5The 
mean difference in concentration (log10 pg/ml) between luteal and follicular phase visits in women with a menstrual 
cycle. 6The mean difference in concentration (log10 pg/ml) between women with amenorrhoea (all visits) and women 
with a cycle (all visits). 7The mean difference in concentration (log10 pg/ml) between visits with PSA present versus 
absent, for visits with the same presence and phase of menstrual cycle. 8The mean difference in concentration (log10 
pg/ml) between visits at which the vaginal pH was 4.0–4.5, or >4.5, each compared to <4, for visits with the same 
presence and phase of menstrual cycle. 9The mean difference in concentration (log10 pg/ml) between visits with 
vaginal discharge present versus absent, for visits with the same presence and phase of menstrual cycle. 10The mean 
difference in concentration (log10 pg/ml) between visits with cervical mucus present versus absent for visits with the 
same presence and phase of menstrual cycle. 11The mean difference in concentration (log10 pg/ml) between visits 
with cervical epithelial findings present versus absent, for visits with the same presence and phase of menstrual cycle. 
Cervical epithelial findings included abrasions, oedema, ecchymosis, petechiae, erythema, and ulcers.
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not been reported in those studies: L. crispatus was often accompanied by L. vaginalis; L. jensenii and L. gasseri 
were never present in most women; and E. coli was regularly present in almost all women. Another important 
pathobiont in the vaginal niche is Streptococcus agalactiae, and unfortunately, we only have qPCR data for that 
organism at baseline29. In a cross-sectional baseline analysis of all 430 women in the Vaginal Biomarkers Study 
using qPCRs, 16% had S. agalactiae29 and 28% E. coli in their VMB16. The limited number of other molecular 
VMB studies that reported on S. agalactiae and E. coli carriage showed varying results, with generally lower detec-
tion in studies that employed 16 S sequencing compared to qPCR18,30,31. Vaginal carriage of these pathobionts 
should be further investigated, preferably by qPCR in longitudinal studies, given their associations with vaginitis, 
reproductive health, and neonatal meningitis and sepsis32.
In women with a normal VMB throughout the study, variations in concentrations of soluble immune media-
tors were greater within women over time than between women, which is in agreement with other studies12,33,34. 
In the women developing BV, incident BV was associated with increased concentrations of proinflammatory 
cytokines and decreased concentrations of the antiprotease elafin and IP-10. Other studies have reported sim-
ilar proinflammatory profiles associated with BV, as well as increased proteolytic activity35–38. IP-10 findings 
across studies are more difficult to interpret (see below). It should be noted that incident or recurrent urogeni-
tal infections other than BV could have been responsible for some of the variation in immune mediators seen. 
However, none of the 80 women in this study had symptomatic vaginal candidiasis throughout the study and 
C. albicans, detected only occasionally and never more than twice in the same women, was present in low con-
centrations in the majority of women. Furthermore, we screened all women for STIs at baseline and selected 
women without STIs (with the exception of chronic HSV-2 infection) for this sub-study. Only women with 
clinician-observed signs of urogenital infections during the eight-week follow-up period were retested for STIs, 
but such clinician-observed signs were rare (Table 1). We therefore believe that incident or recurrent STIs during 
the eight-week follow-up period were uncommon.
We assessed several other potential correlates of VMB bacteria as well as immune mediator concentra-
tion variations in women with a normal VMB throughout the study: the presence and phase of the menstrual 
cycle, the presence of PSA as a marker of recent sex, and recent vaginal cleansing. Amenorrhoeic women had 
a reduced concentration of lactobacilli, (notably L. crispatus), compared to women with a menstrual cycle 
even after controlling for PSA presence and recent vaginal cleansing, and this may be due to the induction of 
a hypo-oestrogenic state during injectable progestin use. Current evidence suggests that the VMB destabilising 
effect of hypo-oestrogenism in these women is larger than any potential protective effect associated with the 
absence of regular menstrual bleeding30. Amenorrhoeic women also had increased concentrations of several 
proinflammatory immune mediators. This is in agreement with results from two African studies (Tanzania and 
South Africa/Kenya)39,40 but in contrast to the results of a recent study in Kenyan women that showed sustained 
decreases in IL-6, IL-8, and IL-1RA after initiation of depot medroxyprogesterone acetate (DMPA) injectable con-
traception41. The comparison groups in these studies differed, with our study comparing amenorrhoeic injectable 
Figure 3. Presence/absence and concentration of vaginal microbiota over the eight week study period in 
women with incident BV (Nugent 7–10). Each box depicts one visit for a particular woman. The shading 
of the box indicates the concentration level (in log10 geq/ml) of each taxon with darker colours depicting a 
higher concentration. If the species was absent the box is white. Boxes bordered by a red line are the first BV 
visit for that woman. Boxes in yellow denote visits with an intermediate Nugent score of 4–6 if present before 
development of BV.
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progestin users with all other women, the Tanzanian and South Africa/Kenya studies comparing current DMPA 
users with women not using hormonal contraception, and the Kenyan study comparing women before and after 
initiation of DMPA use. It is possible that DMPA use is immunosuppressive initially as it binds to the corticoster-
oid receptor with an affinity similar to that of cortisol42, but becomes proinflammatory with prolonged use due to 
increasing hypo-oestrogenism which in turn can lead to VMB dysbiosis and vaginal wall atrophy.
We did find some differences in VMB bacteria and the concentration of immune mediators in samples col-
lected during luteal phase visits compared to follicular phase visits, but these patterns were not consistent. While 
levels of both oestrogen and progesterone are higher in the luteal phase than the follicular phase of the menstrual 
cycle, we sampled women around days 9 and 23 of their cycles, and these time points do not correspond with peak 
hormone levels. Oestrogen in particular is known to associate with higher concentrations of lactobacilli17,43,44. We 
did see increases in concentrations of Lactobacillus genus, L. crispatus, and L. jensenii at luteal phase visits, but 
these did not reach statistical significance. The differences in mean immune mediator concentrations between 
the luteal and follicular phases that we observed were not seen in the earlier mentioned Tanzanian study, and that 
study assessed menstrual cycle stage more carefully by urine pregnanediol 3-glucuronide testing39.
Vaginal sex in the last 24–48 hours as measured by the presence of PSA in vaginal swab eluates was associated 
with concentrations of various lactobacilli, with L. iners showing the greatest reduction. PSA presence was also 
associated with higher concentrations of IL-6, IL-12(p70), and IP-10. Similar effects of recent vaginal sex on 
the VMB have been previously reported by us33 and by others17,45–47. A direct effect was demonstrated in vitro 
when seminal plasma was co-cultured with cervical epithelial cells48. The VMB-destabilising and proinflamma-
tory effects of sexual activity are likely due to the direct effect of seminal fluid as condom use seems to prevent 
them45,49. Recent vaginal cleansing was not significantly associated with any changes in VMB bacteria or immune 
mediator concentrations in any of our analyses.
Using data from all 80 women, we investigated the direct associations between the concentrations of VMB 
bacteria and vaginal immune mediator concentrations over time while controlling for presence and phase of 
the menstrual cycle and PSA presence. Perhaps the most significant finding was that a higher ‘composite 
qPCR vaginal health score’ (suggesting better vaginal health) was associated with decreased concentrations of 
Visit before the first 
incident BV visit First incident BV visit1 Mean concentration 
difference P3Mean concentration2 Mean concentration2
VMB bacteria
Triple taxa qPCR vaginal health score4 5.44 0.20 −5.24 <0.001
Lactobacillus genus 7.60 6.09 −1.51 0.005
L. crispatus 1.91 0.86 −1.05 0.250
L. iners 5.84 4.85 −0.99 0.080
L. vaginalis 2.76 1.42 −1.35 0.021
G. vaginalis 2.11 4.95 2.84 <0.001
A. vaginae 0.20 4.12 3.92 <0.001
E. coli 3.04 2.75 −0.29 0.709
P. bivia 1.76 3.13 1.38 0.003
Immune mediators
Total protein 8.29 8.12 −0.17 0.026
IL-1α 1.23 1.49 0.26 0.157
IL-1β 0.69 1.35 0.66 0.003
IL-6 0.77 1.06 0.28 0.081
IL-8 2.07 2.29 0.22 0.104
IL-12(p70) −0.00 0.22 0.22 0.024
IL-1RA 4.71 4.99 0.28 0.250
IP-10 2.63 2.25 −0.39 0.046
MIP-1β 0.70 0.89 0.18 0.372
GM-CSF 0.34 0.28 −0.06 0.157
G-CSF 1.96 1.96 0.11 0.579
Elafin 5.07 4.81 −0.26 0.010
SLPI 4.80 4.62 −0.18 0.287
Table 4. Differences in VMB bacteria and immune mediator concentrations in 40 women with incident BV 
between the visit before the incident BV visit and the incident BV visit. Abbreviations: BV = bacterial vaginosis; 
G-CSF = granulocyte colony stimulating factor; GM-CSF = granulocyte macrophage colony stimulating factor; 
IL = interleukin; IP-10 = interferon-inducible protein 10; MIP-1β = macrophage inflammatory protein 1β; 
SLPI = secretory leukocyte protease inhibitor; VMB = vaginal microbiota. 1The first incident BV visit was visit 
2 for 16 women, visit 3 for 7 women, visit 4 for 11 women and visit 5 for 6 women. 2Expressed in log10 genome 
equivalents per mL (geq/ml) for VMB bacteria and log10 pg/ml for immune mediators. 3Wilcoxon signed rank 
tests. 4log10 geq/ml (Lactobacillus genus)−log10 geq/ml (G. vaginalis + A. vaginae).
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all three modelled proinflammatory cytokines (IL-1α, IL-8, and IL-12(p70)) and an increased concentration 
of IP-10. Unfortunately, the sample size of this sub-study was small; some statistically significant associations 
in the cross-sectional analyses of the Vaginal Biomarkers Study baseline data showed the same trends as this 
sub-study but did not reach statistical significance22. When interpreting the cross-sectional16,22 and longitudinal 
data together, we conclude that Lactobacillus species are associated with an increase in IP-10 and reductions (L. 
crispatus, L. vaginalis) or no change in multiple proinflammatory cytokines; BV-associated bacteria are associated 
with a decrease in IP-10 and increases in multiple proinflammatory cytokines; and E. coli and S. agalactiae are 
associated with increases in IP-10 and multiple proinflammatory cytokines (the S. agalactiae data are unpub-
lished). A cross-sectional Canadian study employing 16 S sequencing to characterise the VMB reported very 
similar results: a decrease in IP-10 and increases in multiple proinflammatory cytokines in women with BV (com-
munity state type (CST)-4), and no inflammation but an increase in IP-10 in women with a L. iners dominated 
VMB (CST-3)50. A longitudinal South African study also found significant increases in multiple proinflammatory 
cytokines at visits during which vaginal dysbiosis was detected, but no association with IP-1012. IP-10 (also known 
as CXCL10) is induced by type I and II interferons and TNF-α and is a ligand for the CXCR3 receptor51–53. IP-10 
levels are generally elevated in uncontrolled viral infection, but a reduction of IP-10 levels by pathogenic bacteria, 
and particularly combinations of bacteria, has been described before54–57. The significance of this remains unclear. 
A recent study among women in South Africa by Masson et al. found that increased IL-1β and reduced IP-10 
concentrations in female genital secretions of HIV-negative women predicted the presence of BV and/or other 
treatable discharge-causing STIs37. The combination of these two biomarkers identified a significantly higher 
proportion (77%) of women with BV and treatable STIs than clinical criteria (19%). Consequently, the authors 
suggested to explore the use of those biomarkers in the detection of BV and discharge causing STIs38.
Our study had some limitations. Unfortunately, we could not afford to quantify all relevant bacteria and 
immune mediators in all longitudinal samples from all participants of the Vaginal Biomarkers Study. The current 
sub-study design was considered a next best but feasible alternative. This design required us to select women 
based on longitudinal Nugent scores, which are a cruder way of classifying VMBs than the molecular methods we 
employed in the sub-study. However, multiple studies have shown a good correlation between the two methods 
in classifying woman as having a lactobacilli-dominated or dysbiotic VMB1, with the molecular testing adding 
nuance. Our sub-study design also reduced our statistical power, especially related to the potential effects of VMB 
minority species. Due to the stringent selection criteria, our results may not be generalisable to all women.
In conclusion, our well-controlled longitudinal data confirm the inflammatory nature of anaerobic vaginal 
dysbiosis and E. coli colonisation, recent vaginal sex, and progestin-injectable use. While anaerobic vaginal dys-
biosis or BV is by far the most common vaginal dysbiosis, high abundance of E. coli, S. agalactiae, and other 
pathobionts as a distinct inflammatory vaginal dysbiosis deserves further study. The roles of a selection of the 
vaginal mediators (IL-1α, IL-1β, IL-8, IL-12, IP-10) with or without the composite qPCR vaginal health score as 
predictive biomarkers for the above conditions warrant further investigation.
Methods
Ethical approvals. The study protocol was approved by the Ethical Review Committee, Kenyatta National 
Hospital, Kenya; the Human Research Ethics Committee (Medical), University of the Witwatersrand, South 
Africa; the Rwanda National Ethics Committee, Rwanda; the Institutional Review Board of the Institute of 
Tropical Medicine (ITM), Belgium; and the ethics committees of the Ghent University Hospital in Ghent and the 
Antwerp University Hospital in Antwerp, Belgium. In addition the study was approved by the National Council 
of Science and Technology, Kenya; and the National Health Research Committee, Rwanda. All methods described 
below were performed in accordance with the relevant guidelines and regulations.
IL-1α IL-8 IL-12(p70) IP-10 Elafin PSA Amenorrhoea Luteal phase
Est.1 p1 Est.1 p1 Est.1 p1 Est.1 p1 Est.1 p1 Est.1 p1 Est.1 p1 Est.1 p1
Triple taxa qPCR 
vaginal health score2 −1.14 0.005 −1.55 0.002 −1.80 <0.001 2.53 <0.001 0.34 0.383 −1.07 0.002 0.80 0.160 0.52 0.118
Lactobacillus genus3 0.02 0.939 −0.75 0.003 −0.42 0.105 0.92 <0.001 −0.21 0.301 −0.49 0.005 −0.37 0.135 0.34 0.054
L. crispatus3 0.49 0.353 −0.49 0.466 −0.05 0.921 0.79 0.098 −0.39 0.317 −0.55 0.218 −1.36 0.053 0.29 0.452
L. iners3 −0.58 0.020 0.77 0.010 −0.50 0.108 0.49 0.011 −0.42 0.078 −0.38 0.076 −0.26 0.280 −0.10 0.696
L. vaginalis3 0.24 0.563 0.60 0.289 −0.25 0.562 −0.43 0.276 −0.00 0.991 −0.14 0.688 0.18 0.722 −0.06 0.849
P. bivia3 0.52 0.004 0.78 0.001 0.03 0.917 −0.69 <0.001 0.20 0.296 −0.05 0.759 −0.29 0.214 −0.19 0.268
E. coli3 −0.00 0.995 0.55 0.049 −0.60 0.054 0.28 0.139 −0.05 0.832 0.29 0.160 −0.05 0.812 −0.14 0.491
Table 5. Longitudinal associations between VMB bacteria and immune mediator concentrations among all 
visits of all 80 women (with Nugent 0–3 throughout and with incident BV) over the eight week study period. 
Abbreviations: BV = bacterial vaginosis; Est = model estimate; IL = interleukin; IP-10 = interferon-inducible 
protein 10; qPCR = quantitative polymerase chain reaction; PSA = prostate-specific antigen; VMB = vaginal 
microbiota; vs = versus. 1From mixed effects multiple regression models with each item in the first column as 
the outcome, individual women as random effects, and fixed effects for all variables in the first row. 2log10 geq/
ml (Lactobacillus genus)−log10 geq/ml (G. vaginalis + A. vaginae). 3For women with the bacteria present during 
at least 75% of visits and excluding the visits during which the bacteria was absent. We only included VMB 
bacteria that were consistently present (in at least 75% of the visits) in at least 25% of women.
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Study participants and clinic visits. This paper describes a longitudinal analysis of 80 women who were 
part of the Vaginal Biomarkers Study, which enrolled a total of 430 women at three study sites: the International 
Centre of Reproductive Health Kenya in Mombasa, Kenya; the Wits Reproductive Health and HIV Institute 
in Johannesburg, South Africa and Rinda Ubuzima in Kigali, Rwanda. In the original study design, women 
were recruited into predefined groups: HIV-negative adult women (N = 219), adolescents (N = 60), and preg-
nant women (N = 60) in Kenya and South Africa; HIV-positive women (N = 30) and HIV-negative sex workers 
(N = 30) in Rwanda; and women engaging in traditional vaginal practices in South Africa (N = 31). For the cur-
rent analysis, we selected 40 women who had a normal VMB (defined as a Nugent score of 0–3) at five consecutive 
visits over eight weeks and 40 women who had a normal VMB at baseline and incident BV (defined as a Nugent 
score of 7–10) at one of the four follow-up visits over eight weeks. Additional selection criteria were: none of the 
relevant samples were missing; women tested negative for pregnancy, HIV, syphilis, N. gonorrhoeae, C. trachoma-
tis, T. vaginalis), and vaginal candidiasis at baseline and did not become HIV-positive or pregnant (reference 
group) during follow-up; and reported not to engage in traditional vaginal practices (such as the use of cloth, 
lemon juice or detergents inside the vagina) at baseline. Women with positive HSV-2 serology at baseline were 
included due to the high prevalence of 34%. A total of 54 and 48 women qualified for the reference and incident 
BV groups, respectively, and 40 women were selected for each group from among the qualifying women at ran-
dom. No matching was done.
Women were followed for five consecutive visits over eight weeks. The visits were tightly scheduled around the 
menstrual cycle with the enrolment visit (visit 1) scheduled shortly after the last day of the menstrual period on 
day 9 (±2 days) of the cycle; the absence of menses was verified during vaginal examination at this visit. The next 
four visits were scheduled with two week intervals over two menstrual cycles (visits 2–5). Thus, visits 3 and 5 coin-
cided with day 9 (±2 days) of the menstrual cycle (the follicular phase) and visits 2 and 4 with day 23 (±2 days) or 
the luteal phase. The same visit schedule was followed for women using hormonal contraception, including those 
who were amenorrhoeic due to progestin-injectable use. At baseline, eligible women interested in participating 
provided written informed consent, were interviewed about sociodemographic and behavioural characteristics, 
underwent a physical and vaginal examination, and were tested for HIV and the above-mentioned reproductive 
tract infections. Interviews and vaginal examinations were also done at all subsequent visits.
Sample collection. At each of the five visits included in this sub-study, the following samples were col-
lected before any other procedures in the following order: two sterile flocked swabs (Copan Diagnostics, Inc., 
Murrieta, CA) that were rotated against the mid-portion of the vaginal wall under visual inspection, dipped in the 
posterior fornix and carefully removed to prevent contamination; and a CVL that was obtained by gently flush-
ing 10 ml normal saline through the speculum and aspirating the fluid from the posterior fornix. At each study 
site, one trained clinician performed all the examinations using one standard operating procedure to minimise 
inter-clinician variability.
Sample processing. CVLs were collected in 15 ml falcon tubes, kept on ice for transport (2–8 °C), and pro-
cessed within a maximum of one hour after collection. CVLs were centrifuged at 1,000 x g for 10 minutes at 4 °C 
and supernatants (~9 ml) were aliquoted into three fractions; two of approximately 4 ml each and one of 1 ml. The 
aliquots were stored at −80 °C locally. CVLs and vaginal swabs, frozen at −80 °C, were shipped in batches using 
a temperature-monitored dry shipper to the central laboratory at the ITM in Antwerp, Belgium, where they were 
stored at −80 °C before analysis of soluble immune mediators and VMB bacteria.
Characterisation of vaginal microbiota. Vaginal Gram-stained slides were examined and scored at the 
ITM using the Nugent method14. qPCR was performed on extracted DNA from vaginal swab eluates for the fol-
lowing ten species and one genus: Lactobacillus genus, L. crispatus, L. gasseri, L. iners, L. jensenii, L. vaginalis, A. 
vaginae, G. vaginalis, E. coli, P. bivia, and C. albicans and in duplicate at the ITM and at the University of Ghent, 
Belgium, as previously described16,18. The number of organisms was expressed as genome equivalents per ml (geq/
ml); the genomic concentration was calculated using the described genomic sizes of the type strains.
Quantification of soluble immune mediators in CVLs. Concentrations of the cytokines IL-1α, IL-1β, 
IL-6 and IL-12(p70), MIP-1β, IP-10 and IL-8, and growth factors GM-CSF and G-CSF in CVLs were measured 
at the ITM using the Bio-Plex™ human cytokine assay kit (Bio-Rad Laboratories NV-SA, Nazareth, Belgium) 
as previously described33. Elafin, SLPI, IL-1RA and the total protein concentration in CVLs were measured in 
the Laboratory of Genital Tract Biology, Brigham and Women’s Hospital, Boston, MA, USA. Elafin and SLPI 
were quantified using ELISA kits from R&D Systems (Minneapolis, MN) following manufacturers’ instructions. 
IL-1RA was measured using the Meso Scale Discovery (MSD) multiplex platform and Sector Imager 2400 (MSD, 
Gaithersburg, MD). The MSD Discovery Workbench Software was used to convert relative luminescent units into 
protein concentrations (pg/ml) using interpolation from several log calibrator curves. Total protein in CVLs was 
determined by a bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, IL) using the Victor 2 counter. 
Optical densities were read at 450 nm with a second reference filter of 570 nm using a Victor2 multi-label reader 
and WorkOut Software (PerkinElmer, Waltham, MA).
Prostate-specific antigen detection. PSA was measured in vaginal swab eluates using the Seratec® PSA 
semiquant assay (Seratec Diagnostica, Göttingen, Germany). A volume of 150 µl of the eluate, in diluted phos-
phate buffered saline (1,200 μl; 1 part phosphate buffered saline and 9 parts saline, pH 7.4), was centrifuged for 
10 min at 13,000 x g. After centrifugation, 120 µl of supernatant was used for testing according to the manufac-
turer’s instructions.
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Data analysis. Statistical analyses were performed using Stata 13 (StataCorp, College Station, TX), SAS 9.4 
(SAS Institute Inc, Cary, NC) and R 3.0.1 (The R Foundation, Vienna, Austria). Over the five study visits, the 
detection of individual VMB bacteria by qPCR was classified as follows: never present; sporadically present (pres-
ent at 25% or fewer visits); regularly present (present at 26–74% of visits) and consistently present (present at 75% 
or more visits). The concentrations of VMB bacteria (in geq/ml) and immune mediators (in pg/ml) were log10 
transformed in all analyses.
For the women with a normal VMB throughout the study: Longitudinal variations in the concentrations of 
VMB bacteria were assessed in mixed effects linear regression models for those VMB bacteria consistently pres-
ent in at least 25% of the women with a normal VMB throughout the study. All models included one VMB bacte-
ria as the outcome and individual women as random effects. We added the following fixed effects: sampling in the 
luteal (visits 2 and 4) versus follicular phase (visits 1, 3 and 5) of the menstrual cycle, the absence (amenorrhoea 
due to progestin-injectable use) or presence of a menstrual cycle (either a natural cycle or regular withdrawal 
bleeds during combined contraceptive use), presence of PSA as a marker of sex within the last 24–48 hours23,24, 
and recent vaginal cleansing (the evening or morning just prior to the study visit).
For the women with a consistently normal VMB, mixed effects linear regression models were also fitted with 
each immune marker concentration as the outcome, individual women as random effects, and including presence 
and phase of the menstrual cycle as fixed effects. Further mixed effects linear regression models for each marker 
as outcome, controlled for presence and phase of the menstrual cycle, were fitted separately for the following 
covariates: vaginal pH category (<4.0, 4.0–4.5, >4.5), presence of clinician-observed abnormal vaginal discharge, 
cervical mucus, a cervical epithelial finding (abrasion, laceration, ecchymosis, petechiae, erythema, or ulcer), 
vaginal cleansing, and PSA. These covariates were selected based on previous cross-sectional analyses in the same 
study population16,21,22 and based on the published literature7,39.
In the women with incident BV, we assessed the mean change in concentrations of VMB bacteria and immune 
mediators between the visit preceding the first incident BV visit and the first incident BV visit using Wilcoxon 
signed rank tests. Furthermore, the direct associations between VMB bacteria concentrations (for VMB bacteria 
consistently present in at least 25% of the women) and immune marker concentrations (IL-1α, IL-8, IL-12, IP-10, 
and elafin) were determined in mixed effects linear regression models in all 80 women. All models included the 
concentration of an individual VMB bacterium as the outcome, individual women as random effects, and the 
following fixed effects: each immune mediator concentration, PSA presence, and presence and phase of menstrual 
cycle. We also considered a ‘triple taxa qPCR vaginal health score’ based on the concentrations of three key VMB 
bacteria [log10 (Lactobacillus genus)−log10 (G. vaginalis + A. vaginae)] as the outcome because this score was 
shown to be the best indicator of vaginal health in the Vaginal Biomarkers Study26.
Data availability. According to the Institute of Tropical Medicine’s policy, all data are available from 
the Institute of Tropical Medicine Institutional Data Access for researchers who meet the criteria for access 
to confidential data. Requests for data access can be made by emailing Mr. Jef Verellen, Quality Specialist at 
ITMresearchdataaccess@itg.be.
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